A Phase 1 interventional study of KQB198 and Dasatinib in Hematologic Malignancies and Adult, sponsored by Kumquat Biosciences Inc.. Active, not recruiting at 29 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Kumquat Biosciences Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 823 studies in Hematologic Neoplasms with a site in United States — 182 open to participants now, 278 under way, 12 of them phase 3. Hematologic Neoplasms · United States.
Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 527th largest by enrollment of the 660 interventional ones that give a count, is one of 31 that started in 2024, is one of 197 in phase 1, reaches primary completion later than 115 of the 275 other live ones, and was the 752nd registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.
Browse Hematologic Neoplasms studies →182 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
University of Arizona · Sites in United States
Ages up to 65
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Orum Therapeutics USA, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
823 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 278 · Phase 2 280 · Phase 3 43 · Phase 4 9
First in 1989; this study’s year is marked. 31 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 40 across the 660 interventional studies, 150 across the 157 observational. Of the 497 that completed or were terminated, 208 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
215 of 823 have an industry lead sponsor. The 10 most frequent:
Kumquat Biosciences Inc. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Kumquat Biosciences Inc. has 1 study filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
90 of the studies in Hematologic Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07504458Phase 3Quetzal TherapeuticsPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | 2027-03 |
| NCT04188418Phase 3M.D. Anderson Cancer CenterFentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients | 2027-08-31 |
| NCT02862275National Cancer Institute (NCI)Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | 2026-11-21 |
| NCT05745285University of MiamiLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | 2026-11-30 |
| NCT02203903Catherine BollardMulti-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies | 2026-11-30 |
Add all 90 to your calendar (.ics) → With an account.
Among the 823 studies in Hematologic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 1 and Part 2, Cohort B Participants Only:
Part 2, Cohort A Participants Only:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: KQB198
Drug: KQB198 · Drug: Dasatinib
Drug: KQB198 · Drug: Dasatinib
Drug: KQB198 · Drug: Dasatinib
Drug: KQB198
Drug: KQB198
Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1)
Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, SAEs, and DLTs, from first dose of study treatment to 28 days after last dose of study treatment.
Time frame: 28 Days
Recommended Phase 2 Dose (RP2D) (Part 1)
Evaluate safety and assess number of patients with dose-limiting toxicity to determine the RP2D.
Time frame: Up to 30 months
Efficacy of study treatment and optimal biologic dose, as measured by molecular response (MR) per European Leukemia Network (ELN) 2020 Guidelines (Part 2).
Molecular response is the percentage of BCR-ABL fusion protein found in blood. Calculation of molecular response in Part 2 Cohort A will be the proportion of subjects that experience molecular response 4 (MR4) during the time period from 1st dose of study treatment until 6 months of study treatment. Calculation of molecular response in part 2 cohort B will be the proportion of subjects that experience molecular response 3 (MR3) during the time period from 1st dose of study treatment until 6 months of study treatment.
Time frame: Up to 6 Months
Efficacy of Study Treatment
Efficacy of study treatment as measured by molecular response (MR) at 3, 6, 9, and 12 months, and anytime.
Time frame: Up to 30 months
Efficacy of Study Treatment
Efficacy of study treatment as measured by duration of response (DOR). DOR is defined as the time from the date when the response is first observed till the date the response is lost or death, whichever is earlier.
Time frame: Up to 30 Months
Efficacy of Study Treatment
Efficacy of study treatment as measured by time to response (TTR). Response assessments will be summarized by all reported response categories at each visit.
Time frame: Up to 30 months
Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 2)
Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, SAEs from first dose of study treatment to 28 days after last dose of study treatment.
Time frame: 28 Days After Last Dose
Concentration-Time Curve (AUC)
Time frame: Up to 30 months
Maximum Plasma Concentration (Cmax)
Time frame: Up to 30 months
Time to Maximum Plasma Concentration (tmax)
Time frame: Up to 30 months
Started Dec 2024 (actual). Primary completion is estimated for Mar 2027, 27 months after the start.
Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 27 months is below that.
Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SOS1 Inhibitor MRTX0902
Kumquat Biosciences Inc.